Evidence map›Paper›PMID 40258994›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Choice of steroids for intratympanic therapy- a retrospective comparison.

Lennart Weitgasser, Stefan Tschani, Magdalena Kogler, Maximilian Armstorfer, Wolfgang Schimetta, Sebastian Roesch

Abstract readComparative Study
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lennart WeitgasserDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg, 5020, Austria. l.weitgasser@salk.at.ORCID http://orcid.org/0000-0002-1577-8056
Stefan TschaniDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg, 5020, Austria.
Magdalena KoglerDepartment of Clinical Pharmacy and Drug Information, Landesapotheke Salzburg, Salzburg, Austria.
Maximilian ArmstorferDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg, 5020, Austria.
Wolfgang SchimettaDepartment of Applied Systems Research and Statistics, Johannes Kepler Universität, Linz, Austria.
Sebastian RoeschDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg, 5020, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeComparison of dexamethasone phosphate (DXA) and triamcinolone acetonide (TCA) for intratympanic therapy (IT) in patients with unilateral idiopathic sudden sensorineural hearing loss (ISSNHL) to reveal a potential superiority regarding the efficiency to improve hearing function.

methodsRetrospective, monocentric, two-armed cohort-study. Analysis of clinical and audiometric data of patients treated with IT for unilateral ISSNHL. 118 adults, who received IT with DXA (n = 67) or TCA (n = 51) were included. Main outcome parameters were hearing improvement in percent and decibel (dB) in relation to the healthy ear within a follow-up period of three months. Response to therapy was defined as an improvement of at least 10dB in affected frequencies.

resultsMedian improvement was 24.6% and 6.2 dB in the DXA group, 31.4% and 10.0 dB in the TCA group. For the response analysis, 7 patients dropped out. Of the remaining 111 patients, 27 (43,5%; 95%CI 30,9-56,7) in the DXA and 26 (53,0%; 95%CI 38,2-67,4) in the TCA group showed response. Analysis of the outcome parameters showed no statistically remarkable difference (p < 0,05) between the two cohorts. The difference of initial pure tone average between the affected and healthy ear and the time between symptom onset and first IT, was confirmed as an influencing factor to the outcome.

conclusionFor intratympanic treatment of ISSNHL dexamethasone phosphate and triamcinolone acetonide seem equivalent considering its ability to improve hearing function. A more severe hearing loss and a short duration between onset and therapy may favor the chance of hearing recovery.

Indexed as

DexamethasoneGlucocorticoidsHearing Loss, SensorineuralHearing Loss, SuddenTriamcinolone AcetonideAdultAgedAudiometry, Pure-ToneFemaleHumansInjection, IntratympanicMaleMiddle AgedRetrospective StudiesTreatment OutcomeDexamethasonedexamethasone 21-phosphateGlucocorticoidsTriamcinolone AcetonideDexamethasoneIntratympanic therapySNHLSudden hearing lossTriamcinolone acetonide

Identifiers

PMID40258994
PMCPMC12423152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.